$ABBV Company News Investors warm up to Gilead's test

New Post Public Reply Private Reply Replies (0) Message Board

Jan 13, 2014 at 10:29 AM

$ABBV Company News

Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - Russ Britt
Enanta's run continues up through the close; shares jump 28% 6:01 p.m. Dec. 10, 2013 - Russ Britt
More success for hepatitis C drug means a surge for Enanta shares 1:42 p.m. Dec. 10, 2013 - Russ Britt
Tesla cleared in German probe; Apple up on UBS upgrade 4:56 p.m. Dec. 3, 2013 - Sue Chang
FDA approving drugs faster, and it may stay that way, report says 6:10 p.m. Nov. 18, 2013 - Russ Britt
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Mixed bag of earnings ends up badly for two health-care firms 10:22 a.m. Oct. 25, 2013 - Russ Britt
Microsoft, Amazon, Zynga are stocks to watch 4:31 a.m. Oct. 25, 2013 - Sue Chang
FDA recommends new limits on pain drugs 10:25 p.m. Oct. 24, 2013 - Thomas M. Burton
Abbott Labs sets a brisk earnings pace by beating income forecasts 10:43 a.m. Oct. 16, 2013 - Russ Britt
AbbVie net falls 16% on separation costs 8:58 a.m. July 26, 2013 - MarketWatch.com
4 things traders should know for the next 24 hours 4:46 p.m. July 25, 2013 - blogs.marketwatch.com
The Next 24: Starbucks Surges 4:13 p.m. July 25, 2013 - MarketWatch
Pharmacyclics seeks fast-track drug approval, makes double-digit gain 10:09 a.m. July 10, 2013 - Russ Britt
European regulators set precedent with approval of new copycat drugs 2:04 p.m. June 28, 2013 - Russ Britt
No rest for the weary, or even the savvy, in Wall Street carnage 4:21 p.m. June 20, 2013 - Russ Britt
Supreme Court satisfies few with ruling on generic drug settlements 4:30 p.m. June 18, 2013 - Russ Britt
Dan Loeb's cheap stock picks 11:39 a.m. June 18, 2013 - Insider Monkey
Pacts that delay sale of generics in jeopardy 1:55 a.m. June 18, 2013 - Brent Kendall
Supreme Court decision on generics hits Actavis, but few other drug firms 11:46 a.m. June 17, 2013 - Russ Britt

Dividend Watch: 5 Stocks Going Ex-Dividend Monday: SBR, DSM, EAD, VTA, ABBV 10:00 a.m. Jan. 10, 2014 - TheStreet.com
Seattle Gentics-AbbVie Deal Expanded - Analyst Blog 5:10 p.m. Jan. 9, 2014 - Zacks.com
Seattle Genetics deepens collaboration with AbbVie 9:36 a.m. Jan. 8, 2014 - Seeking Alpha
Enanta Joins Big Leagues With Hepatitis C Drug 6:15 p.m. Jan. 7, 2014 - Investors Business Daily
Celgene's Stock Should See New All-Time Highs Due To Strong Pipeline 2:14 p.m. Jan. 3, 2014 - Seeking Alpha
The Perfect Portfolio: End Of Year Review 4:28 a.m. Jan. 1, 2014 - Seeking Alpha
BofA lifts target on AbbVie 2:27 p.m. Dec. 31, 2013 - Seeking Alpha
BofA Merrill Lynch Reiterates on AbbVie, Raises PO 9:03 a.m. Dec. 31, 2013 - benzinga.com
Many Key Changes to Goldman Sachs Conviction Buy List for 2014 10:52 a.m. Dec. 30, 2013 - 247WallSt.com
Co-Pays: Skin In The Game If It Ain't Your Skin? 1:33 p.m. Dec. 27, 2013 - Seeking Alpha
Pipeline Update on Santarus Candidate - Analyst Blog 5:10 p.m. Dec. 26, 2013 - Zacks.com
Drugmaker Aptalis Files For IPO After Overhaul 10:50 a.m. Dec. 26, 2013 - Investors Business Daily
Big Pharma Stocks: Year in Review 6:00 a.m. Dec. 24, 2013 - TheStreet.com
Pipeline Progress at Novartis - Analyst Blog 5:42 p.m. Dec. 23, 2013 - Zacks.com
CHMP Positive on Roche's RoActemra's Subcutaneous Formulation - Analyst Blog 11:50 a.m. Dec. 23, 2013 - Zacks.com
Sandoz starts late stage study of Humira biosimilar 3:32 p.m. Dec. 19, 2013 - Seeking Alpha
Healthcare upgrades, downgrades, and initiations for Thursday 9:46 a.m. Dec. 19, 2013 - Seeking Alpha
S&P Stocks Hitting New Highs 4:33 p.m. Dec. 18, 2013 - FOXBusiness
ABBV Dividend Yield Pushes Past 3% 3:09 p.m. Dec. 18, 2013 - TheStreet.com
Gilead's Next Hepatitis C Drug A Hit In Trials 11:32 a.m. Dec. 18, 2013 - Investors Business Daily

Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie 8:59 a.m. Jan. 8, 2014 - BusinessWire
Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix 8:00 a.m. Jan. 8, 2014 - PR Newswire
Conference Calls, Regulatory Filings, and Member Enrollment - Research Report on UnitedHealth Group, AbbVie, Lilly, Actavis, and Humana 8:00 a.m. Jan. 6, 2014 - PR Newswire
Foundation for the NIH Announces First Results of I-SPY 2 Breast Cancer Clinical Trial 1:50 p.m. Dec. 26, 2013 - PR Newswire
Stock Price Movements, FDA Approvals, and Completed Acquisitions - Research Report on AbbVie, Baxter, IDEXX, Kythera Biopharmaceuticals, and Medical Properties Trust 8:00 a.m. Dec. 24, 2013 - PR Newswire
AbbVie to Present at 32nd Annual J.P. Morgan Healthcare Conference 1:00 p.m. Dec. 20, 2013 - PR Newswire
Critical Alerts For First Solar, Viacom, Lowe's, Vertex Pharmaceuticals, and AbbVie Released By InvestorsObserver 9:31 a.m. Dec. 19, 2013 - PR Newswire
Dividends, Regulatory Filings, Merger Agreement, Quarterly Results Schedules, and Share Repurchase Programs - Research Report on AbbVie, Baxter, Cooper, ViroPharma, and Varian Medical Systems 8:05 a.m. Dec. 18, 2013 - PR Newswire
Clinical Trial Results, Share Repurchase Transactions, Stock Price Updates, Appointments, and Investments - Research Report on AbbVie, Express Scripts, Actavis, Bristol-Myers Squibb, and GSK 8:00 a.m. Dec. 13, 2013 - PR Newswire
AbbVie Declares Quarterly Dividend 12:09 p.m. Dec. 12, 2013 - PR Newswire
Stock Price Updates - Research Report on AbbVie, Covance, MannKind, MAKO Surgical, and Envision 8:00 a.m. Dec. 11, 2013 - PR Newswire
Pharma Industry Morning Assessment: Pfizer, Merck & Co., AbbVie, and Zogenix 12:19 p.m. Dec. 10, 2013 - PR Newswire
AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C 8:00 a.m. Dec. 10, 2013 - PR Newswire
Product Recalls, New Appointments, Awareness Campaigns, and Stock Price Movements - Research Report on Abbott, AbbVie, Viropharma, Valeant Pharmaceuticals, and Salix Pharmaceuticals 8:00 a.m. Dec. 2, 2013 - PR Newswire
AbbVie Partners with HIV Community to Launch International Awareness Campaign Focused on Women Living with HIV 9:21 a.m. Nov. 26, 2013 - PR Newswire
Grants and Stock Movements of Major Drug Manufacturers - Research Report on AbbVie, Keryx Biopharmaceuticals, Pacira Pharmaceuticals, Rockwell Medical, and Impax Laboratories 8:00 a.m. Nov. 22, 2013 - PR Newswire
Federal Legislation Support, Philanthropic Activities, and Patent Challenges - Research Report on Mylan, Abbott, Actavis, AbbVie, and Agilent Technologies 8:00 a.m. Nov. 19, 2013 - PR Newswire
Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 6:21 p.m. Nov. 14, 2013 - PR Newswire
AbbVie to Present at Jefferies 2013 Healthcare Conference 8:15 a.m. Nov. 14, 2013 - PR Newswire
Critical Alerts For Johnson and Johnson, AbbVie, Air Products and Chemicals, American Capital, and AFLAC Released By InvestorsObserver 9:31 a.m. Nov. 13, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...